We could not find any results for: Make sure your spelling is correct or try broadening your search.
It looks like you aren't logged in.Click the button below to log in and view your recent history.
Already a member? Sign in
Options Flow
Live Options Flow
Connect with traders and investors in our Follow Feed community.
Explore comprehensive options data and use advanced filters with Options Flow.
Organize and monitor your stock and asset watchlist with Monitor.
Arix Bioscience PLC (ARIX) Holding(s) in Company 24-Jan-2024 / 17:30 GMT/BST
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:
Arix Bioscience Plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name
RTW Investments, LP
City and country of registered office (if applicable)
New York, USA
4. Full name of shareholder(s) (if different from 3.) v
RTW Biotech Opportunities Operating Ltd
St Peter Port, Guernsey
5. Date on which the threshold was crossed or reached vi:
17/01/2024
6. Date on which issuer notified (DD/MM/YYYY):
22/01/2024
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached
25.52
0.00%
25.52%
33,023,210
Position of previous notification (if
applicable)
n/a
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of shares
ISIN code (if possible)
Number of voting rights ix
% of voting rights
Direct
(DTR5.1)
Indirect
(DTR5.2.1)
GB00BD045071
0
SUBTOTAL 8. A
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument
Expiration date x
Exercise/ Conversion Period xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Physical or cash
Settlement xii
Number of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
Roderick Wong
RTW Investments GP LLC
RTW Biotech Opportunities Ltd
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Place of completion
London, UK
Date of completion
19/01/2024
More Arix Bioscience PLC News Articles
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads